Lebrikizumab monotherapy impacts on quality of life scores through improved itch and sleep interference in two Phase 3 trials Vrije Universiteit Brussel
BACKGROUND: Lebrikizumab improved itch, interference of itch on sleep, and quality of life (QoL) in patients with moderate-to-severe atopic dermatitis (AD), in two Phase 3 trials at 16 weeks compared to placebo.
OBJECTIVES: We assess improvements in itch and sleep interference due to itch and their impact on QoL measurements after treatment.
METHODS: Data were analyzed from ADvocate1 (NCT04146363) and ADvocate2 (NCT04178967) ...